L'UE a annoncé vendredi qu'elle avait conclu un accord avec le géant pharmaceutique français Sanofi pour 300 millions de doses d'un vaccin potentiel contre le coronavirus.La Commission européenne, le bras exécutif du bloc qui a négocié l'accord, a déclaré qu'elle autoriserait les 27 pays membres à acheter le vaccin une fois qu'il se sera avéré sûr et efficace.
The announcement comes the same day that the U.S. government said it would provide up to $ 2.1 billion to Sanofi and GSK for the development of a COVID-19 vaccine, as the world continues to fight the pandemic.
As official data revealed that coronavirus lockdowns caused a devastating 12% economic contraction in the EU in the second quarter of 2020, European Commission President Ursula von der Leyen said the bloc was doing it all. what he could to help find a vaccine.
“We are in advanced discussions with several other companies,” she said in a statement, adding that Europe was investing in a “diverse portfolio of promising vaccines”.
This increases our chances of getting an effective cure for the virus quickly. ”
Sanofi hopes to apply for marketing authorization from the European Medicines Agency for a vaccine in June of next year.
The French government welcomed Friday’s announcement as a “decisive step”.
“This future contract will allow each EU member state to order the vaccine under good conditions once it has shown sufficient evidence of its efficacy and safety,” the French government said in a statement.
Six months after the World Health Organization (WHO) declared a global emergency, the novel coronavirus has infected more than 17 million people, with daily cases worldwide now approaching the 300,000 mark.
Death toll in Europe
Europe as a whole has nearly 210,000 deaths for 3.2 million cases, and with infections on the rise in several countries, there are fears that a “second wave” of the pandemic is underway.
The highly restrictive lockdowns applied to deal with the pandemic earlier this year caused economic turmoil and an effective vaccine may be the only long-term solution to the highly contagious respiratory disease.